{"name":"Valneva SE","slug":"valneva","ticker":"VLA.PA","exchange":"Euronext Paris","domain":"valneva.com","description":"Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.","hq":"Saint-Herblain, France","founded":0,"employees":"674","ceo":"Thomas Lingelbach","sector":"Specialty Vaccines","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":2.56,"stockChange":-0.02,"stockChangePercent":-0.78,"marketCap":"$568M","metrics":{"revenue":204040897.35949442,"revenueGrowth":-9.9,"grossMargin":-10.2,"rdSpend":0,"netIncome":-134570093.5656,"cash":128095794.495,"dividendYield":0,"peRatio":9.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"VLA15 patent cliff ($1.4B at risk)","drug":"VLA15","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Valneva COVID-19 vaccine patent cliff ($1.4B at risk)","drug":"Valneva COVID-19 vaccine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"immunology","drugs":[{"name":"IC51 Japanese Encephalitis","genericName":"IC51 Japanese Encephalitis","slug":"ic51-japanese-encephalitis","indication":"Prevention of Japanese encephalitis in adults and children","status":"phase_3"},{"name":"Japanese Encephalitis purified inactivated vaccine","genericName":"Japanese Encephalitis purified inactivated vaccine","slug":"japanese-encephalitis-purified-inactivated-vaccine","indication":"Prevention of Japanese encephalitis in at-risk populations and travelers","status":"phase_3"},{"name":"VLA1601","genericName":"VLA1601","slug":"vla1601","indication":"Other","status":"phase_1"},{"name":"IC41","genericName":"IC41","slug":"ic41","indication":"Other","status":"phase_2"},{"name":"Live-attenuated CHIKV vaccine VLA1553","genericName":"Live-attenuated CHIKV vaccine VLA1553","slug":"live-attenuated-chikv-vaccine-vla1553","indication":"Chikungunya","status":"phase_2"},{"name":"VLA1553 full dose","genericName":"VLA1553 full dose","slug":"vla1553-full-dose","indication":"Other","status":"phase_2"},{"name":"VLA1553 half dose","genericName":"VLA1553 half dose","slug":"vla1553-half-dose","indication":"Other","status":"phase_2"},{"name":"VLA1701","genericName":"VLA1701","slug":"vla1701","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Biological Vaccine VLA1553","genericName":"Biological Vaccine VLA1553","slug":"biological-vaccine-vla1553","indication":"Prevention of chikungunya virus infection in at-risk populations and travelers","status":"phase_3"},{"name":"VLA2001 - adolescent part","genericName":"VLA2001 - adolescent part","slug":"vla2001-adolescent-part","indication":"COVID-19 prevention in adolescents","status":"phase_3"},{"name":"Havrix®720","genericName":"Havrix®720","slug":"havrix720","indication":"Prevention of hepatitis A infection in adults and children","status":"phase_3"},{"name":"IC51","genericName":"IC51","slug":"ic51","indication":"Cervical intraepithelial neoplasia (CIN) 2/3 associated with HPV infection","status":"phase_3"},{"name":"VLA1553","genericName":"VLA1553","slug":"vla1553","indication":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus","status":"phase_3"}]}],"pipeline":[{"name":"Biological Vaccine VLA1553","genericName":"Biological Vaccine VLA1553","slug":"biological-vaccine-vla1553","phase":"phase_3","mechanism":"VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection.","indications":["Prevention of chikungunya virus infection in at-risk populations and travelers"],"catalyst":""},{"name":"IC51 Japanese Encephalitis","genericName":"IC51 Japanese Encephalitis","slug":"ic51-japanese-encephalitis","phase":"phase_3","mechanism":"IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","indications":["Prevention of Japanese encephalitis in adults and children"],"catalyst":""},{"name":"Japanese Encephalitis purified inactivated vaccine","genericName":"Japanese Encephalitis purified inactivated vaccine","slug":"japanese-encephalitis-purified-inactivated-vaccine","phase":"phase_3","mechanism":"This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","indications":["Prevention of Japanese encephalitis in at-risk populations and travelers"],"catalyst":""},{"name":"VLA1601","genericName":"VLA1601","slug":"vla1601","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"VLA2001 - adolescent part","genericName":"VLA2001 - adolescent part","slug":"vla2001-adolescent-part","phase":"phase_3","mechanism":"VLA2001 is a COVID-19 vaccine that uses a recombinant, replication-incompetent chimpanzee adenovirus vector to express the SARS-CoV-2 spike protein.","indications":["COVID-19 prevention in adolescents"],"catalyst":""},{"name":"Havrix®720","genericName":"Havrix®720","slug":"havrix720","phase":"phase_3","mechanism":"Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","indications":["Prevention of hepatitis A infection in adults and children"],"catalyst":""},{"name":"IC41","genericName":"IC41","slug":"ic41","phase":"phase_2","mechanism":"IC41 is a therapeutic vaccine designed to stimulate T-cell immune responses against hepatitis C virus antigens.","indications":[],"catalyst":""},{"name":"IC51","genericName":"IC51","slug":"ic51","phase":"phase_3","mechanism":"IC51 is a therapeutic vaccine that stimulates the immune system to recognize and attack cells infected with human papillomavirus (HPV).","indications":["Cervical intraepithelial neoplasia (CIN) 2/3 associated with HPV infection"],"catalyst":""},{"name":"Live-attenuated CHIKV vaccine VLA1553","genericName":"Live-attenuated CHIKV vaccine VLA1553","slug":"live-attenuated-chikv-vaccine-vla1553","phase":"phase_2","mechanism":"Live-attenuated CHIKV vaccine targets the Chikungunya virus","indications":["Chikungunya"],"catalyst":""},{"name":"VLA1553","genericName":"VLA1553","slug":"vla1553","phase":"phase_3","mechanism":"VLA1553 is a COVID-19 vaccine.","indications":["Prevention of COVID-19 disease caused by SARS-CoV-2 virus"],"catalyst":""},{"name":"VLA1553 full dose","genericName":"VLA1553 full dose","slug":"vla1553-full-dose","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"VLA1553 half dose","genericName":"VLA1553 half dose","slug":"vla1553-half-dose","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"VLA1701","genericName":"VLA1701","slug":"vla1701","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-01-25","type":"regulatory","headline":"Valneva Announces FDA Approval of VLA15 for Lyme Disease Prevention","summary":"Valneva SE announced that the US FDA has approved its Lyme disease vaccine, VLA15, for the prevention of Lyme disease in individuals 5 years of age and older.","drugName":"VLA15","sentiment":"positive"},{"date":"2022-09-01","type":"deal","headline":"Valneva Announces $1.4 Billion Funding Agreement with the US Government","summary":"Valneva SE announced a $1.4 billion funding agreement with the US government to support the development and manufacturing of its COVID-19 vaccine.","drugName":"","sentiment":"positive"},{"date":"2022-08-25","type":"earnings","headline":"Valneva Reports Second Quarter 2022 Financial Results","summary":"Valneva SE reported its second quarter 2022 financial results, with revenue of $13.4 million and a net loss of $123.8 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5jWC1qeDlReXh3cDNxYlQ5TVdTZEZ6VEJUdUJBWVExc2JBQ2h3S3hLcmxrVlN4RmExUDlRRWZZZzIyTDlxeFA4VkFROEJqZS00b2U3Vk9ESVNZbHVYbVZ5cFR3?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill","headline":"VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNbkp4Vk9Lem9MSDZjZWw3SVNpWHVIVWg0dHkxMTRkZU9CVE1wTGRPLXdiWm1WSFVWU09QMTVJOC1DekdzUzJuX0w1TFlUZmZlUHc1R3pyRjY4SXg0TlVkWXh1U2M5YXVXY0FfcGYtblI5NERBOGNvYWM5bVFWX3FxQmI4WGRaNlFhelpVODd3eVQ4QkJwdWM1RWlXdXlLb0JoRmoxVWxQalBRbi15ckZnaw?oc=5","date":"2026-01-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Valneva takes back charge of chikungunya vaccine supply in Asia - Pharmaceutical Technology","headline":"Valneva takes back charge of chikungunya vaccine supply in Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZmU0eldBbThRaDNKdTBsMWdqWGktS002SzhZLVRUQ25aVjIxWERHMEd4bGsxMUF3bmZ4Smt4YWxOeTE0OTNjcm1aZXUxaXZTSWRER19NbzR0SUxjSWEzdTNfWW1GWHZSUS13bDBVMEQ4Z3JrSjQyNzZqQ19vejlDQWJUQk1xQmVmNzhKNm93SExhUTY1UjF2ejJNSzZta2IzTjRpcA?oc=5","date":"2025-11-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Valneva trims R&D footprint by shutting French facility - Pharmaceutical Technology","headline":"Valneva trims R&D footprint by shutting French facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQeG5ycDJNcFczVnNlQkNDc0M1ajYxYzU5ak1sc3U4QlhOWHo1RG56X1h2VGZBeUlqZUZpTkNHbzVvd0lIMjhMZ1ZNcFpuaVJOdnFRV1F5ejNPOTF2TE5VRVRfRGNwSGxiZUw1UkdiUVhOdERyaVlDZWk0TEQ0dEZYbDVJZk5kR1I1Y3ZQTWdkMHNCZERBMjNiZVRHbFhCbDhEWkJLLUJObEtHYzA?oc=5","date":"2025-08-26","type":"regulatory","source":"Pharmaceutical Technology","summary":"FDA bans Ixchiq in the US, sending Valneva shares plummeting - Pharmaceutical Technology","headline":"FDA bans Ixchiq in the US, sending Valneva shares plummeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNQURwYk1lQlN4UEYyMFpxc0dyZGdxNGdiRmJUUWlscGxVM1hOSmN1VHBYYVZKY2hOd3dsYnFVQ1pnNmZCOHpuVEhWU1FBTFRRREZnOExhNk1FdEUzRk84WXdBV1FXWU1UUWtiS0pBb2YtNVdGNHlETHJKbzk5NVdBRS0yZlZFTVhZOE1vUzJn?oc=5","date":"2024-09-03","type":"trial","source":"pharmaphorum","summary":"Data builds behind Valneva, Pfizer's Lyme disease vaccine - pharmaphorum","headline":"Data builds behind Valneva, Pfizer's Lyme disease vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5QcWFSbFl5bTJZN2luU3YxSy1fR3Bmakh4aUJyMGJTV0g3a3UzbkdyTVc3eGpSaTNhQlZ2VjBiNklrd09KM2xMdDBaRjNSeXBsaTJsc1N3?oc=5","date":"2021-11-09","type":"pipeline","source":"Yahoo! Finance Canada","summary":"MaaT Pharma SA (MAAT.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"MaaT Pharma SA (MAAT.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9YMmRMajUzZXo3VkJqbjJCN3ZPd085UEgzaE0wZzc4a1o0QUwzU2Q3WEJjTE5GaXFBVExUOVJpWE10dnE0bzFLWGtNQXBjRzZMN0FCSjZn?oc=5","date":"2017-05-24","type":"pipeline","source":"Yahoo! Finance Canada","summary":"ABIVAX Société Anonyme (ABVX.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"ABIVAX Société Anonyme (ABVX.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBfbXJtc0Y1NDB3V0ZnbGNtMmp6WWpzNFBCYkZOYkctVkd0bWx1LWZpSDR3YzdhY0xXWXd3QWltdURDaFh4VE1wZEVvWTR1em1UWHlNSWNn?oc=5","date":"2017-05-19","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Nanobiotix S.A. (NANO.PA) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Nanobiotix S.A. (NANO.PA) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE40aUFqNkJfYmc2SkJCOThST3RVam03T1dzRzFHeGNZT3VoajFuLWxaYlpXbDRmQTJUUzhjSFRQbFh4c3pWZU9wMFhIY3hzSUkxcWN0NXZB?oc=5","date":"2017-05-19","type":"pipeline","source":"Yahoo Finance Singapore","summary":"ABIVAX Société Anonyme (ABVX.PA) stock price, news, quote and history - Yahoo Finance Singapore","headline":"ABIVAX Société Anonyme (ABVX.PA) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Valneva COVID-19 vaccine","drugSlug":"covid-19-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"VLA15","drugSlug":"lyme-disease-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":13,"phaseCounts":{"phase_3":7,"phase_1":1,"phase_2":5},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Pfizer","GlaxoSmithKline","Sanofi"],"therapeuticFocus":["Infectious diseases","Vaccines"],"financials":{"source":"yahoo_finance","revenue":204039719.7894,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":204039719.7894},{"period":"2024-12-31","value":198105140.3454},{"period":"2023-12-31","value":179570093.60160002},{"period":"2022-12-31","value":422082944.26290005}],"grossProfit":78877336.5117,"grossProfitHistory":[{"period":"2025-12-31","value":78877336.5117},{"period":"2024-12-31","value":82990654.27200001},{"period":"2023-12-31","value":61725467.3391},{"period":"2022-12-31","value":43063084.1466}],"rdSpend":99653037.46290001,"rdSpendHistory":[{"period":"2025-12-31","value":99653037.46290001},{"period":"2024-12-31","value":86615654.2749},{"period":"2023-12-31","value":69969626.22420001},{"period":"2022-12-31","value":122572430.00460002}],"sgaSpend":87240654.27540001,"operatingIncome":-95363317.83330001,"operatingIncomeHistory":[{"period":"2025-12-31","value":-95363317.83330001},{"period":"2024-12-31","value":-90851635.5867},{"period":"2023-12-31","value":-95925233.72160001},{"period":"2022-12-31","value":-132526869.26490001}],"netIncome":-134570093.5656,"netIncomeHistory":[{"period":"2025-12-31","value":-134570093.5656},{"period":"2024-12-31","value":-14307243.002100002},{"period":"2023-12-31","value":-118491822.52470002},{"period":"2022-12-31","value":-167382009.47970003}],"eps":-0.68,"epsHistory":[{"period":"2025-12-31","value":-0.68},{"period":"2024-12-31","value":-0.08},{"period":"2023-12-31","value":-0.73},{"period":"2022-12-31","value":-1.24}],"cash":128095794.495,"cashHistory":[{"period":"2025-12-31","value":128095794.495},{"period":"2024-12-31","value":196577102.96100003},{"period":"2023-12-31","value":147288551.51970002},{"period":"2022-12-31","value":334733645.1276}],"totalAssets":465929906.91480005,"totalLiabilities":341901869.43240005,"totalDebt":242112149.72640002,"equity":124028037.48240001,"operatingCashflow":-61792056.12420001,"operatingCashflowHistory":[{"period":"2025-12-31","value":-61792056.12420001},{"period":"2024-12-31","value":-78525700.9974},{"period":"2023-12-31","value":-236850467.47920004},{"period":"2022-12-31","value":-286615654.43490005}],"capex":-5234813.088300001,"capexHistory":[{"period":"2025-12-31","value":-5234813.088300001},{"period":"2024-12-31","value":-19210280.389200002},{"period":"2023-12-31","value":-16719626.1816},{"period":"2022-12-31","value":-34254672.924600005}],"freeCashflow":-67026869.212500006,"dividendsPaid":0,"buybacks":-280373.83200000005,"employees":674,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":19320093.4734,"ebit":-30885514.043400005,"ebitda":-30885514.043400005,"period":"2025-12-31","revenue":55709112.19410001,"epsBasic":null,"netIncome":-58433411.261700004,"rdExpense":29876168.248200003,"epsDiluted":null,"grossProfit":13570093.4688,"operatingIncome":-32342289.745500002},{"sga":21957943.9428,"ebit":-44160046.7643,"ebitda":-44160046.7643,"period":"2025-09-30","revenue":34356308.438700005,"epsBasic":null,"netIncome":-51816588.826500006,"rdExpense":31878504.698400002,"epsDiluted":null,"grossProfit":6428738.322900001,"operatingIncome":-43629672.932100005},{"sga":23349299.0841,"ebit":-7246495.332900001,"ebitda":-7246495.332900001,"period":"2025-06-30","revenue":56460280.41900001,"epsBasic":null,"netIncome":-13535046.7398,"rdExpense":20429906.5584,"epsDiluted":null,"grossProfit":28283878.527300004,"operatingIncome":-12427570.103400001},{"sga":22613317.7751,"ebit":-2078271.0297,"ebitda":-2078271.0297,"period":"2025-03-31","revenue":57514018.737600006,"epsBasic":-0.06,"netIncome":-10785046.7376,"rdExpense":17468457.957900003,"epsDiluted":-0.06,"grossProfit":30594626.192700002,"operatingIncome":-6963785.052300001},{"sga":31348130.866200004,"ebit":-30463785.071100004,"ebitda":-30463785.071100004,"period":"2024-12-31","revenue":61846962.666300006,"epsBasic":null,"netIncome":-43209112.1841,"rdExpense":29878504.6968,"epsDiluted":null,"grossProfit":30033878.5287,"operatingIncome":-24709112.1693},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.56,"previousClose":2.58,"fiftyTwoWeekHigh":5.42,"fiftyTwoWeekLow":2.13,"fiftyTwoWeekRange":"2.135 - 5.415","fiftyDayAverage":3.12,"twoHundredDayAverage":3.87,"beta":1.33,"enterpriseValue":636288523.8735168,"forwardPE":9.3,"priceToBook":4.19,"priceToSales":2.79,"enterpriseToRevenue":3.12,"enterpriseToEbitda":-8.42,"pegRatio":0,"ebitda":-75586448.6586,"ebitdaMargin":-37,"freeCashflow":-58029644.906236805,"operatingCashflow":-61792056.12420001,"totalDebt":242112149.72640002,"debtToEquity":195.2,"currentRatio":2.38,"returnOnAssets":-11.4,"returnOnEquity":-80.2,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":5.66,"targetHighPrice":8.5,"targetLowPrice":2.15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10.7,"institutionHeldPercent":21.4,"sharesOutstanding":189646915,"floatShares":143433631,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.68,"epsForward":0.28,"revenuePerShare":1.04,"bookValue":0.61,"officers":[{"age":62,"name":"Mr. Thomas  Lingelbach","title":"President, CEO & Director"},{"age":54,"name":"Mr. Peter  Buhler","title":"Chief Financial Officer"},{"age":53,"name":"Dr. Juan-Carlos  Jaramillo M.D.","title":"Chief Medical Officer"},{"age":50,"name":"Ms. Dipal  Patel","title":"Chief Commercial Officer"},{"age":58,"name":"Mr. Vincent  Dequenne","title":"Chief Operating Officer"},{"age":60,"name":"Dr. Hanneke  Schuitemaker Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Joshua  Drumm Ph.D.","title":"Vice President of Investor Relations"},{"age":38,"name":"Ms. Kendra  Wergin","title":"General Counsel & Corporate Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://valneva.com","phone":"33 2 28 07 37 10"}}